מונטהלוקאסט אינובמד 5 מ"ג

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

MONTELUKAST AS SODIUM 5 MG

Disponível em:

INOVAMED LTD

Código ATC:

R03DC03

Forma farmacêutica:

CHEWABLE TABLETS

Via de administração:

PER OS

Fabricado por:

SYNTHON B.V., NETHERLANDS

Grupo terapêutico:

MONTELUKAST

Indicações terapêuticas:

Montelukast Inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.Montelukast Inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast Inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast Inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

Data de autorização:

2012-01-01